ArticleJournal of molecular and cellular cardiology plus2026
Acetyl-CoA synthetase 2 maintains cytosolic acetyl-CoA homeostasis to preserve mitochondrial integrity and attenuate cardiac dysfunction under chronic β-adrenergic stress.
Article in Journal of molecular and cellular cardiology plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is often accompanied by metabolic remodeling; however, the contribution of compartment-specific acetyl-CoA homeostasis to mitochondrial dysfunction remains unclear. Here, we identify acetyl-CoA synthetase 2 (ACSS2) as an important regulator of cytosolic acetyl-CoA homeostasis and mitochondrial integrity under chronic β-adrenergic stress. Chronic isoproterenol stimulation induced heart failure with reduced ejection fraction in mice and selectively suppressed myocardial ACSS2 expression, resulting in depletion of cytosolic acetyl-CoA without altering total cellular levels. Similar changes were observed in H9c2 cardiomyoblasts exposed to prolonged β-adrenergic stimulation. Genetic deletion of ACSS2 recapitulated this metabolic disturbance, leading to mitochondrial structural remodeling and impaired oxidative respiration without evidence of altered mitochondrial biogenesis. Mechanistically, ACSS2 deficiency was associated with compartment-specific alterations in protein acetylation, characterized by reduced cytosolic acetylation and increased mitochondrial acetylation. Mitochondrial dysfunction was reversible, as long-term supplementation with butyrate restored mitochondrial respiratory capacity. Conversely, cardiomyocyte-targeted ACSS2 overexpression preserved cytosolic acetyl-CoA levels and was associated with improved mitochondrial respiratory function and attenuated cardiac dysfunction in vivo under chronic β-adrenergic stress. Together, these findings suggest that ACSS2-dependent cytosolic acetyl-CoA homeostasis contributes to the maintenance of mitochondrial quality and cardiac resilience, highlighting the importance of metabolic compartmentalization in heart failure pathophysiology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.